Targeted drug zongertinib shows strong results for HER2-mutant lung cancer in clinical trial
The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 mutations – with manageable side effects,…